Farmas USA

Día de FED

The Federal Reserve is likely to raise short-term interest rates by a quarter percentage point after its two-day policy meeting concludes Wednesday, the sixth such move since late 2015.

The biggest questions will be answered when officials release new projections for unemployment, inflation, economic growth and interest rates in the years ahead, and when Fed Chairman Jerome Powell holds a press conference.

The central bank releases its statement and the forecasts at 2 p.m. EDT, and Mr. Powell will take questions at 2:30 p.m. 

https://www.wsj.com/articles/fed-set-to-raise-rates-issue-new-economic-projections-1521624601?mod=e2twe

 

Venga! Dia de reversals !!!

Para Abril (sin determinar) se espera que Trump anuncie medidas para bajar el precio de los medicamentos. Aunque las promesas de trump sabemos lo que valen...y a saber qué tipo de medidas, pero este es un tema que ya sabemos que es fundamental y muy delicado. Así que atentos:

President Donald Trump promised to bring down prescription drug prices on Monday, saying U.S. citizens pay far more than people in other countries do for the same product and that his administration would announce new measures in about a month. 

https://www.reuters.com/article/us-usa-trump-pharma/trump-says-he-is-working-to-lower-prescription-drug-prices-idUSKBN1GV2MN

Interesante, no los conocia como tal , tal vez muchos de uds aqui si.

------------

Try This ETF Pair To Round Out Your Biotech Exposure

Mar. 15, 2018 6:36 PM ET

Summary

If you're using funds, such as IBB and BBH, for biotech exposure in your portfolio, you're mostly investing in the industry's biggest names.

IBB has nearly 30% of its assets invested in the big 4 biotech companies - Gilead, Biogen, Amgen and Celgene.

Equal weighting the biotech sector might be a better way to balance out risk and improve returns.

I propose using a pair of equal-weight biotech ETFs in place of IBB.

Dave Dierking, CFA

ETF investing, portfolio strategy, dividend investing, retirement

The  Virtus LifeSci Biotech Products ETF ( BBP) and the  Virtus LifeSci Biotech Clinical Trials ETF ( BBC) essentially split the biotech universe into two groups.

BBP invests in products stage companies. They have already successfully completed multiple human clinical trials and have received FDA approval to sell and market a drug.

BBC invests in clinical trials stage companies. These companies are typically younger, smaller companies which do not have a drug approved, but instead focus on testing their experimental drug candidates in human clinical trials.

https://seekingalpha.com/article/4156921-try-etf-pair-round-biotech-exposure

Ayer no pude seguir la sesión, pero había dejado unas órdenes de compra. Entraron éstas:

- CELG: A 86.70$

- SGYP: A 1.92$

- (OFFTOPIC) AMD: A 11$

SGYP 

Short Interrest decreciente 

En 1.90/1.93 tiene el 61 % RFibo de la t.alcista que inicio despues del ER

`

https://www.nasdaq.com/symbol/sgyp/institutional-holdings

-----------------                              -------                              ------

Tras la reciente aprobacion de la FDA para IBS-C debe aumentar los scrips en los proximos ER

https://ir.synergypharma.com/all-sec-filings/content/0001104659-18-019004/0001104659-18-019004.pdf

GLYC
Al final 7M a $17. Yo había dejado una orden por si se acercaba a cerrar el gap pero se dio la curva antes de tiempo y acabó verde.

Con PIRS me pasó igual esta semana pasada, apuré la orden y se escapó.

GLYC

Misma situación. Dejé orden no al cierre del gap, al inicio, en 15,55 y ni eso... Viendo que tenía pasta de sobras, sin ninguna necesidad de diluir, estos offerings son rebote casi asegurado en empresas que sus estudios van bien. Supongo que sería el mismo caso de PIRS que comentas, pero no la sigo.